Jiménez-Huete A, Lievens P M, Vidal R, Piccardo P, Ghetti B, Tagliavini F, Frangione B, Prelli F
Department of Pathology, New York University Medical Center, New York 10016, USA.
Am J Pathol. 1998 Nov;153(5):1561-72. doi: 10.1016/S0002-9440(10)65744-6.
We have investigated the proteolytic cleavage of the cellular (PrPC) and pathological (PrPSc) isoforms of the human prion protein (PrP) in normal and prion-affected brains and in tonsils and platelets from neurologically intact individuals. The various PrP species were resolved after deglycosylation according to their electrophoretic mobility, immunoreactivity, Sarkosyl solubility, and, as a novel approach, resistance to endogenous proteases. First, our data show that PrPC proteolysis in brain originates amino-truncated peptides of 21 to 22 and 18 (C1) kd that are similar in different regions and are not modified by the PrP codon 129 genotype, a polymorphism that affects the expression of prion disorders. Second, this proteolytic cleavage of PrPC in brain is blocked by inhibitors of metalloproteases. Third, differences in PrPC proteolysis, and probably in Asn glycosylation and glycosylphosphatidylinositol anchor composition, exist between neural and non-neural tissues. Fourth, protease-resistant PrPSc cores in sporadic Creutzfeldt-Jakob disease (CJD) and Gerstmann-Sträussler-Scheinker F198S disease brains all have an intact C1 cleavage site (Met111-His112), which precludes disruption of a domain associated with toxicity and fibrillogenesis. Fifth, the profile of endogenous proteolytic PrPSc peptides is characteristic of each disorder studied, thus permitting the molecular classification of these prion diseases without the use of proteinase K and even a recognition of PrPSc heterogeneity within type 2 CJD patients having different codon 129 genotype and neuropathological phenotype. This does not exclude the role of additional factors in phenotypic expression; in particular, differences in glycosylation that may be especially relevant in the new variant CJD. Proteolytic processing of PrP may play an important role in the neurotropism and phenotypic expression of prion diseases, but it does not appear to participate in disease susceptibility.
我们研究了人类朊病毒蛋白(PrP)的细胞型(PrPC)和病理型(PrPSc)异构体在正常和受朊病毒感染的大脑以及神经功能正常个体的扁桃体和血小板中的蛋白水解切割情况。对各种PrP种类进行去糖基化处理后,根据其电泳迁移率、免疫反应性、十二烷基肌氨酸钠溶解度,以及作为一种新方法,根据对内源蛋白酶的抗性进行分离。首先,我们的数据表明,大脑中PrPC的蛋白水解产生了21至22kd和18kd(C1)的氨基截短肽,这些肽在不同区域相似,且不受影响朊病毒疾病表达的多态性PrP密码子129基因型的修饰。其次,大脑中PrPC的这种蛋白水解切割被金属蛋白酶抑制剂阻断。第三,神经组织和非神经组织之间存在PrPC蛋白水解的差异,可能也存在天冬酰胺糖基化和糖基磷脂酰肌醇锚组成的差异。第四,散发性克雅氏病(CJD)和格斯特曼-施特劳斯勒-谢inker F198S病大脑中抗蛋白酶的PrPSc核心都有完整的C1切割位点(Met111-His112),这排除了与毒性和纤维形成相关的结构域被破坏的可能性。第五,内源性蛋白水解PrPSc肽的图谱是所研究的每种疾病的特征,因此无需使用蛋白酶K即可对这些朊病毒疾病进行分子分类,甚至可以识别具有不同密码子129基因型和神经病理表型的2型CJD患者体内的PrPSc异质性。这并不排除其他因素在表型表达中的作用;特别是,糖基化差异在新型变异型CJD中可能尤为重要。PrP的蛋白水解加工可能在朊病毒疾病的嗜神经性和表型表达中起重要作用,但似乎不参与疾病易感性。